Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.65 |
| ▸ | TACR2 | P21452 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TACR3 | P29371 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | PTAFR | P25105 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378018 | 0.91 | TACR1 (0.60) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL707404 | 0.91 | TACR1 (0.60) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL13378009 | 0.89 | TACR1 (0.78) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL13378022 | 0.89 | TACR1 (0.78) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL10038440 | 0.84 | TACR1 (0.47) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL706858 | 0.83 | TACR1 (0.60) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL12646295 | 0.80 | TACR1 (0.75) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL3176248 | 0.80 | TACR1 (0.75) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL24067973 | 0.79 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL16280736 | 0.79 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018136554-A1 | USE OF NEUROKININ-1 ANTAGONISTS AS ANTITUSSIVES | MENLO THERAPEUTICS INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2010-04-29 | — | — | US | disclosed |
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2010-04-29 | — | — | US | disclosed |
| WO-2008124143-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, HTR1D, TACR2 | TACR1 1/4885TACR2 3/4885CYP3A4 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.